Research programme: vaccines - Capo Therapeutics

Drug Profile

Research programme: vaccines - Capo Therapeutics

Alternative Names: Anti-Aβ vaccine - Capo Therapeutics; Anti-tau vaccine - Capo Therapeutics; Anti-β amyloid vaccine - Capo Therapeutics; AV 1950D; AV-1947D; AV-1948D; AV-1949D; AV-1950R; AV-1959D; AV-1959R; AV-1960CP; AV-1980D; AV-1980R; AV-1991CP; AV-1992CP

Latest Information Update: 10 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Flinders University; University of California at Irvine
  • Developer Capo Therapeutics
  • Class Vaccines
  • Mechanism of Action Amyloid beta-protein modulators; Immunostimulants; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 05 Jul 2016 Capo Therapeutics in-licenses vaccines against Alzheimer's disease from Flinders University and University of California
  • 05 Jul 2016 Preclinical trials in Alzheimer's disease in USA (Parenteral)
  • 05 Jul 2016 Preclinical trials in Parkinson's disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top